News: Advanced Herbal Medicines
30 May 2024
Dexa Group advocates for the development of traditional herbal medicine through Indonesia Indigenous Modern Medicine in the webinar titled “Jamu: Dulu, Kini, dan Nanti.”
Indonesia's potential wealth in natural resources, as the second-largest country in terms of biodiversity, boasting over 28 thousand species of plants and 2,848 medicinal plants, presents significant opportunities for the development of natural medicine and Indonesia Indigenous Modern Medicine (OMAI) phytopharmaceuticals. Dra. Reri Indriani, Senior Expert Pharmacist and Food Supervisor…
28 October 2023
Stunting Rate Reaches 34,9%, Dexa Medica Collaborates with BKKBN in Educating Hundreds of Midwives in Jember
In the 2024 State Budget and Revenue (APBN), President Joko Widodo allocated IDR 186.4 trillion or 5.6 percent for the health sector. One of the primary goals is to reduce the prevalence of stunting in Indonesia to 14 percent by 2024. To accelerate the stunting reduction target of 14 percent…
21 March 2023
Medicinal Syrup is Safe, Caca Tengker Recommends Stimuno Phytopharmaceuticals
The Indonesian Pharmaceutical Companies Association (GP Farmasi) held an interactive dialogue entitled "Safe Medicinal Syrups for Children". It was revealed that the requirement for safe syrup preparations is in accordance with the provisions of the Food and Drug Administration (BPOM). "BPOM in conducting evaluations, in issuing permits, many standards are…
4 November 2022
Dexa Group’s Strategic Support for Indonesian Pharmacy Resilience and Independence: Indonesia Indigenous Modern Medicine Phytopharmaceutical
The pharmaceutical business is still working toward independence and health security due to the changes in the market brought on by the pandemic circumstances, the global financial crisis, and the high US Dollar exchange rate against the Rupiah. Dexa Group presented three significant initiatives for pharmaceutical resilience and independence with…
12 August 2022
The Ministry of Health Continues to Encourage the Use of Phytopharmaceuticals in Health Service Facilities
The government primarily focuses on developing phytopharmaceuticals to create a system of health resilience and domestic pharmaceutical self-reliance. Launching the Phytopharmaca Formulary and promoting its usage in medical institutions are examples of the government's commitment to fostering the use of phytopharmaceuticals. The Director General of Pharmaceuticals and Medical Devices at…
5 August 2022
Dexa Group’s Commitment to Encourage the Production of Natural Medicine Raw Materials for National Independence
With more than 28000 plant species and 2,848 medicinal plants, Indonesia has the second-highest biodiversity in the world. Its natural resources hold tremendous promise for developing phytopharmaceuticals and herbal medicines, including Indonesia Indigenous Modern Medicine (IIMM). Penny K. Lukito, head of the Food and Drug Supervisory Agency (BPOM), stated that…
8 July 2022
Prevent Stunting, Dexa Group’s Green Pharmacy Becomes The Partner of BKKBN
Indonesia's 29th National Family Day (Harganas) was celebrated with the theme "Let's Prevent Stunting for Stunting-Free Family". President Joko Widodo (Jokowi) said that the government had appointed the National Population and Family Planning Agency (BKKBN) to reduce the prevalence of stunting to 14% in 2024. Therefore, BKKBN collaborates with several…
13 May 2022
HerbaASIMOR Products Aid in the Reduction of Stunting Rates
According to the Indonesia Nutrition Status Survey (SSGI), in 2021, the prevalence of stunting in Indonesia will be 24.4 percent, a 6.4 percent decrease from 30.8 percent in 2018. To meet the goal of reducing stunting prevalence to 14 percent by 2024, the Population Agency and the National Family Planning…
8 December 2021
Dexa Group Appreciated by Government for Contribution to Improving National Industry Competitiveness through OMAI Research and Innovation
Taking an active role in increasing the competitiveness of the national industry through research and sustainable technological innovation in the pharmaceutical sector, Dexa Laboratories of Biomolecular Sciences (DLBS) received the Rintisan Teknologi Industri 2021 award from the Ministry of Industry of the Republic of Indonesia. The award was handed over…
1 September 2021
Dexa Group Ramps Up Business in SE Asia by Launching Glorious Dexa Singapore Pte. Ltd.
Dexa Group, the leading pharmaceutical company from Indonesia, is ramping up its business in Southeast Asia with the launch of Glorious Dexa Singapore, Pte. Ltd. (GDS) based in Singapore. Dexa Group has exported medicines to various countries starting with Myanmar since 1993 and began exporting international standard medicines to Singapore…
